IBT
VNDA icon

International Biotechnology Trust’s Vanda Pharmaceuticals VNDA Stock Holding History

International Biotechnology Trust’s Portfolio VNDA Stock Details VNDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-62,905
Closed -$1.02M – 63
2017
Q2 		$1.02M Sell
62,905
-72,912
-54% -$1.05M 0.39% 49
2017
Q1 		$1.9M Hold
135,817
– – 0.73% 33
2016
Q4 		$2.17M Buy
+135,817
New +$2.18M 0.98% 23

Other funds holding VNDA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
RCAMU
Rothschild & Co Asset Management US Stamford, Connecticut $6.58B AUM 4.5% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

International Biotechnology Trust's VNDA Position: Q3 2017 in Review

International Biotechnology Trust sold out of Vanda Pharmaceuticals (VNDA) in Q3 2017, closing a stake of 62,905 shares — an estimated $1.02M sold.

International Biotechnology Trust first reported a position in VNDA in Q4 2016 and held it in 3 quarters. The position peaked at $2.17M in Q4 2016. 137 funds tracked by Wall St. Rank hold VNDA as of Q3 2017.

  • International Biotechnology Trust reported no remaining Vanda Pharmaceuticals position as of Q3 2017 after selling out during the quarter.
  • International Biotechnology Trust sold 62,905 Vanda Pharmaceuticals shares in Q3 2017, an estimated $1.02M.
  • International Biotechnology Trust first reported a position in Vanda Pharmaceuticals in Q4 2016 and held it in 3 quarters.
  • International Biotechnology Trust's Vanda Pharmaceuticals position peaked at $2.17M in Q4 2016.
  • 137 funds tracked by Wall St. Rank held Vanda Pharmaceuticals as of Q3 2017.

Based on International Biotechnology Trust's 13F filing for Q3 2017, filed 2 Mar 2018.